Skip to main content
Premium Trial:

Request an Annual Quote

Mapmygenome India Launches, Partners with Brain Resource

NEW YORK (GenomeWeb News) – Personal genomics firm Mapmygenome India launched on Tuesday with the announcement of a partnership with Brain Resource.

The Hyderabad, India-based company offers services including a personal genetic profiling product called Genomepatri which includes information about traits, diseases, and drug responses based on an individual's DNA sample.

In partnership with Brain Resource, Mapmygenome also is offering a product called Mapmybrain for brain wellness. Mapmybrain comprises two solutions, WebNeuro for assessing an individual's cognitive strengths and weaknesses, and MyCalmBeat, a personal stress reduction monitor.

Brain Resource is a cognitive tool development shop with offices in San Francisco and Ultimo, Australia.

"With 12 years of expertise in the genomics space, we felt it was time to bring personal genomics to India," Anu Acharya, CEO of Mapmygenome, said in a statement. "With our products and services, we hope to make a positive impact on the early detection of life threatening diseases and conditions."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.